IMPEDE VTE Score (Myeloma)
IMPEDE-VTE score for venous-thromboembolism risk in multiple myeloma on therapy; the weighted sum maps to a low/intermediate/high 6-month VTE band.
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Immunomodulatory agent
- Yes
- Dexamethasone dose
- High-dose (≥ 160 mg/month) — +4
- Prior VTE
- Yes
Result: IMPEDE VTE 13 — high VTE risk.
The tool opens with these values already filled in. Replace them with your own.
What the result means
- Bands
- ≤ 3 low, 4–7 intermediate, ≥ 8 high VTE risk.
What you enter
- Immunomodulatory agent (+4)
- BMI ≥ 25 kg/m² (+1)
- Pelvic / hip / femur fracture (+4)
- Erythropoietin-stimulating agent (+1)
- Dexamethasone dose
- Doxorubicin (+3)
- Asian ethnicity (−3)
- Prior VTE (+5)
The other 2 fields
- Tunneled line / central venous catheter (+2)
- Existing thromboprophylaxis
How this is calculated
- Weights
- IMiD +4, BMI ≥ 25 +1, fracture +4, ESA +1, dexamethasone +4/+2, doxorubicin +3, Asian −3, prior VTE +5, CVC +2, prophylaxis −4/−3.
Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019;94(11):1176-1184. Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.